Observational Study to Evaluate Health Status of Chronic Obstructive Pulmonary Disease (COPD) Patients in Response to Real-life Treatments in Thailand

AstraZeneca1 site in 1 country684 target enrollmentJuly 2010

ConditionsChronic Obstructive Pulmonary Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Chronic Obstructive Pulmonary Disease
Sponsor: AstraZeneca
Enrollment: 684
Locations: 1
Primary Endpoint: Changes in PEF and overall CCQ score
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate health status of uncontrolled Chronic Obstructive Pulmonary Disease (COPD) patients in response to treatments in clinical practice.

Detailed Description

MC MD

Registry

clinicaltrials.gov

Start Date

July 2010

End Date

March 2012

Last Updated

13 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

AstraZeneca

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Provision of informed consent prior to any study specific procedures
•Male or non-pregnant female aged \>40 years
•A clinical diagnosis of COPD with FEV1/ FVC \<0.70 and require combination or modified therapy
•Smoke \> 10 Pack Year

Exclusion Criteria

•Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
•Participation in a clinical study (precluding non-interventional study or registry) during the last 3 months

Outcomes

Primary Outcomes

Changes in PEF and overall CCQ score

Time Frame: between the first visit and after 12 (plus or minus 1) weeks

Secondary Outcomes

Difference of the changes of PEF and overall CCQ score comparing between various treatments(between the first visit and after 12 (plus or minus 1) weeks)